Abbott receives CE Mark for Navitor™, the Latest-Generation Transcatheter Aortic Valve Implantation (TAVI) System for Aortic Stenosis treatment
On May 17, 2021, Abbott received CE Mark for its latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor™. This marks the minimally invasive device availability in Europe for patients with severe aortic stenosis having high or extreme surgical risk.
The company is advancing TAVI therapies with its Navitor valve that offers physicians and patients less invasive options to treat heart diseases using Abbott's industry-leading FlexNav™ delivery system. The Navitor device is imp...
